DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. - Wikidata - awgldk - TriplyDB

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

http://www.wikidata.org/entity/Q44513230

about

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Bortezomib: the evidence of its clinical impact in multiple myeloma.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.The use of novel agents in the treatment of relapsed and refractory multiple myeloma Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.Thalidomide for the treatment of multiple myeloma.Evolving treatment strategies for myeloma.Thalidomide and immunomodulatory drugs in the treatment of cancer.Targeted therapy in multiple myeloma.Current treatment options for myeloma.Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model.Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group.Thalidomide in multiple myeloma: past, present and future.Current status of new drugs for the treatment of patients with multiple myeloma.Investigational treatments for multiple myeloma.Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.Bilateral breast plasmacytoma: a clinical case report The Arkansas approach to therapy of patients with multiple myeloma.Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.An update on drug combinations for treatment of myeloma.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.Current trends in multiple myeloma management.Treatment of relapsed and refractory myeloma.Treatment of multiple myeloma in the targeted therapy era.Mobilization of hematopoietic stem cells into the peripheral blood.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Guidelines for the diagnosis and management of multiple myeloma 2011.Thalidomide: an old drug with new action.Relapsed multiple myeloma: who benefits from salvage autografts?Novel agents and new therapeutic approaches for treatment of multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.

P2860

Q33364235-4C427A3E-9190-458D-8E7E-CAD281A77525 Q33400724-AD5C08DF-C6B0-424D-86B0-3189CECED69F Q33973877-33313382-025D-431B-B0D3-86E31323088E Q35097319-BB01B26C-75E2-4489-B877-C1B5914E4A16 Q35157385-AF1B6BBA-D713-4666-9D68-FA480841D3E8 Q35870500-D0D820C2-25FA-4B54-83DE-E3EFA25D660A Q36012354-BF7317BD-F974-48F3-B3F4-AEAD33051A56 Q36040871-42AFDC8F-36C1-4C62-B35E-E76C9574C12E Q36108614-56CD60CD-9470-4EE1-A9B9-96C10463336B Q36163971-5269D906-AFE8-4EE8-BFB2-13544929B908 Q36325234-31CCFFDD-65AD-4387-85FC-DD8B8301F669 Q36331737-67E8CB94-576E-46E6-B962-BECA520B1E5A Q36616493-1F14EA8E-9E7D-4F91-8BC4-077C8AA13C7A Q36649839-D296602F-6392-4A9F-AF86-D6750CFFE508 Q36654336-5B7B1E30-D4DE-4BB0-B93B-995C0B7764BA Q36831384-73B5CFE5-3D5D-4468-AF84-F3BC6FB35AD8 Q36838506-ADD194C9-54CE-42BD-89DD-85A0D271FCFA Q36928574-6C2DFA13-7764-47EF-AF9C-E340B5E22E45 Q37028586-0561C016-76A7-483E-9D61-1CD279A823B9 Q37038414-78ECE0D6-93BE-46DE-99A6-07D2EFA76BE3 Q37038973-B391F01C-B61F-4831-83BE-7A6FA464527A Q37160347-74B2D30E-3458-4C39-A2F8-2F4A25CFBE7B Q37183557-0208296F-B043-4D52-B2D0-F63B17C2BCE9 Q37209929-026D9130-E9A8-4526-8F08-005C7279C601 Q37385547-8252A0E0-D4E2-4818-94F1-15937B10FE3C Q37810088-C30070B7-A05E-4FF2-93B2-382B35E3117D Q37831402-05E010EC-0008-4130-9FB8-18042AB093F3 Q37851944-8BF3B503-EA12-4B9C-A052-E1024C9BD481 Q37875193-3E93C12B-CA62-4747-84A9-F1013087B7C4 Q37974744-BF6029BA-BAD4-4483-A2F0-1872103AFC82 Q38023515-263E668F-8598-4107-ABA1-1338D2B9AB5A Q38261677-896B0F20-A84D-49C4-A461-092556165608 Q38271032-50DB0F00-1139-4929-9919-17797CFD7A43 Q38780843-C6063AE2-98FA-4BA8-A7F7-8020AEEBF5B5 Q39138108-479D7143-E1BA-448B-ACC4-27ED7E8C68D8 Q40763491-E3880AC0-03B8-4EAF-9594-E7F68B7D80E6 Q44758863-6337CB55-882F-4BF4-B1E9-9B71CD17ED9D Q44924114-D2A2FA76-10F4-488D-AB44-9D8A9D0FFDD9 Q45252391-52C7B590-6B2C-41F4-A6C1-893458652F70 Q45395504-6601916B-6D05-438B-A1E9-73D2288B531D

P2860

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

http://www.wikidata.org/entity/Q44513230

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

DTPACE: an effective, novel co ...... treated patients with myeloma.

@en

DTPACE: an effective, novel co ...... treated patients with myeloma.

@nl

type

label

DTPACE: an effective, novel co ...... treated patients with myeloma.

@en

DTPACE: an effective, novel co ...... treated patients with myeloma.

@nl

prefLabel

DTPACE: an effective, novel co ...... treated patients with myeloma.

@en

DTPACE: an effective, novel co ...... treated patients with myeloma.

@nl

P1433

Q44513230-89C31481-6CA8-42D6-8A0F-D429D26F765D

P1476

Q44513230-FC18670A-63FA-4C7C-9E7C-589E7CAF28AA

P2093

Q44513230-42926DBB-EC29-4683-86D5-49CD88BFA1AF

Q44513230-4692D005-8218-4C19-8FD8-CDA177D190E5

Q44513230-8C996861-D8FD-487D-A8FF-2804D82935B0

Q44513230-93EB6731-10F1-4190-8F30-16E2F250DEB4

Q44513230-A0D1EBAF-043E-4C68-9684-6A2EC0134B47

Q44513230-BD42C53E-A5FE-4CCD-BD93-646F21E48B35

Q44513230-E0113BCE-D639-4392-B88A-18B174422A9A

Q44513230-E80783CD-BB71-45F0-8BC5-7121A1D7C6F4

P304

Q44513230-8127B23A-E5CE-4249-8727-0EEAF889D552

P31

Q44513230-B9E2E1F8-2D4E-44C4-9752-15A39249AEB1

P356

Q44513230-C5271410-1B09-40E8-9F40-3907179924EC

P407

Q44513230-B8141AD1-ED81-483B-8D83-39FEE2018723

P433

Q44513230-DCA3E96B-A703-40D4-B2E9-3E3D8949620A

P478

Q44513230-AA6E92C5-C6C5-44B5-98AF-1934DF2E8AC7

P50

Q44513230-17F10A12-81C8-48A6-BD4B-4FCBCA98ADE6

Q44513230-EFB0731D-CC64-4F95-8CE2-B4F6926A909A

P577

Q44513230-85CD11D1-A971-4A10-89CD-848386A7C574

P698

Q44513230-F76B2C24-0F3C-4456-A266-8CB945A57673

P921

Q44513230-0A4AA353-72A0-4E17-B3C4-EBA341ADF96E

Q44513230-0B7CC8C7-E1C1-4208-A638-C1BF03DBF2C7

Q44513230-DBF422BC-4101-47A8-80FE-FDA2E82A5A02

P356

JCO.2003.01.055

P1433

Journal of Clinical Oncology

P1476

DTPACE: an effective, novel co ...... treated patients with myeloma.

@en

P2093

Athanasios Fassas

http://www.w3.org/2001/XMLSchema#string

Choon-Kee Lee

http://www.w3.org/2001/XMLSchema#string

Firas Muwalla

http://www.w3.org/2001/XMLSchema#string

Frits van Rhee

http://www.w3.org/2001/XMLSchema#string

Guido Tricot

http://www.w3.org/2001/XMLSchema#string

Joth Jacobson

http://www.w3.org/2001/XMLSchema#string

Michele Cottler-Fox

http://www.w3.org/2001/XMLSchema#string

Nikhil Munshi

http://www.w3.org/2001/XMLSchema#string

P304

2732-2739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.01.055

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Maurizio Zangari

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12860952

http://www.w3.org/2001/XMLSchema#string

P921